Interactions of angiotensin-converting enzyme, kinins and nitric oxide in circulation and the beneficial effects of ACE inhibitors in cardiovascular diseases

Israel Medical Association Journal

Volumn 2, Issue 12, 2000, Pages 929-934

  Magen, Eli ^a   Viskoper, Reuven J ^a  

^a BARZILAI MEDICAL CENTER   (Israel)

Author keywords

Angiotensin converting enzyme inhibitors; Cardiovascular disease

Indexed keywords

CARDIOLOGY; DISEASES; DRUG INTERACTIONS; DRUG PRODUCTS; ENZYME INHIBITION; ENZYMES; PATHOLOGY; PATIENT TREATMENT;

CARDIOPROTECTION;

BIOMEDICAL ENGINEERING;

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; BRADYKININ; CAPTOPRIL; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KININ; LOSARTAN; NITRIC OXIDE; RAMIPRIL;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CIRCULATION; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; KININS; MALE; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT;

EID: 0034581572     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Interactions among ACE, kinins and NO
2. Some old and some new ideas on kinin metabolism. I.
3. Bioregulation of kinins, kallikreins, kininogens, and kininases
4. Angiotensin I converting enzyme inhibitors potentiate bradykinins' inotropic effects independently of blocking its activation
5. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase
6. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase
7. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans
8. Improved survival in rats administered N°-nitro-L-arginine methyl ester due to converting enzyme inhibition
9. ACE inhibitors are endothelium-dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin
10. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension
11. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide
12. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation
13. Angiotensin H receptor subtype-stimulated formation of endothelial cyclic GMP and prostacyclin is accompanied by an enhanced release of endogenous kinins
14. The conformational change responsible for AT1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII
15. Basal nitric oxide synthesis in essential hypertension
16. Endothelial cells cultured from human umbilical vein release ATP, substance P and acetylcholine in response to increased flow
17. Kinin- and non-kinin-mediated interactions of converting-enzyme inhibitors with vasoactive hormones
18. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors
19. Mechanical strain-induced human vascular matrix synthesis: The role of angiotensin II
20. Effect of bradykinin receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects
21. Nitric oxide activation in the atherosclerotic human coronary circulation
22. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion
23. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
24. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice
25. Novel mechanisms linking angiotensin II and early atherogenesis
26. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling
27. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo controlled trial of cilazapril
28. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling
29. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial
30. Late ACE inhibitor treatment protects old spontaneously hypertensive rats from cardiovascular death
31. Angiotensin Il-induced hypertrophy of adult rat cardiomyocytes is blocked by nitric oxide
32. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats
33. Effects of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors
34. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption
35. Losartan induced apoptosis as a novel mechanism for the prevention of vascular lesion formation after injury
36. Isorenin, pseudorenin, cathepsin D and renin. A comparative enzymatic study of angiotensin-forming enzymes
37. Localization and production of angiotensin II in the isolated perfused rat bean
38. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway
39. Functional role of chymase in angiotensin II formation in human vascular tissue
40. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators